EWING, N.J., Oct. 30, 2014 (GLOBE NEWSWIRE) -- Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that Dr. Lawrence Mayer, President, Founder and Chief Scientific Officer of Celator, will present at the 2014 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in San Diego, California on Wednesday, November 5, 2014, as part of the Advances in Lipid-Based Delivery Systems for Transdermal, Oral, and Parenteral Administered Drugs session. Dr. Mayer's presentation is scheduled at 2:50 p.m. PST/5:50 p.m. EST.
During his presentation titled "Iterative Optimization of Drug Release and Pharmaceutical Stability Properties Yields Liposomal Anticancer Products with Promising Clinical Efficacy and Commercial Potential: the 'Goldilocks Effect,' " Dr. Mayer will discuss Celator's patented low-cholesterol liposomes as a successful delivery system, as demonstrated by their use in the Company's proprietary CombiPlex® platform.
Celator's lead product, CPX-351 (cytarabine:daunorubicin) Liposome for Injection, is based on the Company's CombiPlex technology and is currently in a Phase 3 clinical study in patients with high risk (secondary) acute myeloid leukemia (AML). The Company recently announced the study achieved its target enrollment, and induction response rate results are expected in the second quarter of 2015, with overall survival data expected in the first quarter of 2016.
About Celator Pharmaceuticals, Inc.
Celator Pharmaceuticals, Inc., with locations in Ewing, N.J., and Vancouver, B.C., is a clinical stage biopharmaceutical company that is transforming the science of combination therapy, and developing products to improve patient outcomes in cancer. Celator's proprietary technology platform, CombiPlex®, enables the rational design and rapid evaluation of optimized combinations incorporating traditional chemotherapies as well as molecularly targeted agents to deliver enhanced anti-cancer activity. CombiPlex addresses several fundamental shortcomings of conventional combination regimens, as well as the challenges inherent in combination drug development, by identifying the most effective synergistic molar ratio of the drugs being combined in vitro, and fixing this ratio in a nano-scale drug delivery complex to maintain the optimized combination until exposure to the tumor following administration. Celator's pipeline includes lead product, CPX-351 (a liposomal formulation of cytarabine:daunorubicin) for the treatment of acute myeloid leukemia; CPX-1 (a liposomal formulation of irinotecan:floxuridine) for the treatment of colorectal cancer; a preclinical stage product candidate, CPX-8 (a hydrophobic docetaxel prodrug nanoparticle formulation), being studied by the National Cancer Institute's Nanotechnology Characterization Laboratory; and several programs exploring novel combinations of existing drugs, including molecularly targeted therapies.
For more information, please visit Celator's website at www.celatorpharma.com. Information on ongoing trials is available at www.clinicaltrials.gov.
Forward-Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Celator, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "believe," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements about the efficacy of our CombiPlex® technology, the expected timeline for the availability of data from our Phase 3 clinical study, statements regarding the potential efficacy and therapeutic potential of CPX-351, and our expectations regarding our development plans for CPX-351 and our drug candidates. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the conduct of future clinical studies, enrollment in clinical studies, availability of data from ongoing clinical studies, expectations for regulatory approvals, and other matters that could affect the availability or commercial potential of Celator's drug candidates. Celator undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Celator in general, see Celator's Form 10-K for the year ended December 31, 2013 and other filings by Celator with the U.S. Securities and Exchange Commission.